Pregnancy and thrombosis risk for women without a history of thrombotic events: a retrospective study of the real risks

Elisavet Grouzi¹*, Abraham Pouliakis², Anthi Aktypi³, Anna Christoforidou⁴, Paraskevi Kotsi⁵, Georgios Anagnostou⁶, Aikaterini Foifa⁷ and Emmanouil Papadakis⁸

Abstract

Background: During pregnancy and puerperium women are at high VTE risk. Current guidelines recommend dynamic VTE-risk assessment during pregnancy. Based on related RCOG-guidelines we constructed a digital VTE-risk assessment tool: PATrisks (www.PATrisks.com). Using this tool, we retrospectively evaluated the thrombotic risk in 742 women from our previous work, women who received thromboprophylaxis based on clinical experience for A) pregnancy complications, B) IVF treatment and C) prothrombotic tendency, in order to investigate whether that practice was justified according to the PATrisks scoring system for VTE prevention.

Methods: Women with pregnancy complications [Group-A: 445], women who had undergone IVF [Group-B:132] and women with a prothrombotic tendency (thrombophilia, family history of VTE, other) [Group-C:165] were assessed using the PATrisks scoring system for thrombotic risk. The women were assigned into one of the following risk categories: low (score ≤ 2), intermediate (score = 3) and high (score ≥ 4). Further analysis per risk factor type (pre-existing or obstetric) and for various combinations of them, was also performed. We evaluated thrombotic risk early in pregnancy, and in the peripartum period.

Results: The mean risk score antepartum was higher for women in Group B (3.3 in comparison with 1.9 and 2.0 in Group A and Group C respectively). Moreover, the risk score increased significantly postpartum for all Groups. The chi-square test also proved that there was a higher percentage of women at high or intermediate risk in group B compared to C before birth (55.3% vs. 26.1% respectively, p < 0.0001, OR: 3.5, 95% CI: 2.2 – 5.7) and similarly after birth (85.6% vs. 56.4%, OR: 4.6, 95%CI: 2.6–8.2, p < 0.0001). In total 12 (1.6%) out of 742 women experienced thrombotic events, whether pre- or post-partum.

Conclusions: LMWHs are widely prescribed during pregnancy for a number of indications, even when a proven scientific basis for such a practice is lacking. However, a considerable percentage of women were already at VTE-risk according to PATrisks and might have derived an additional benefit from LMWH in the form of VTE prevention. The rational use of these drugs should be optimized by establishing and implementing routine risk assessment for all pregnant women and by providing the necessary education to healthcare professionals.

Keywords: Low molecular weight heparin, Pregnancy, Venous thromboembolism, Pregnancy complications
causes of maternal morbidity and mortality in developed countries [1].

This is largely attributable to pregnancy-related changes in clotting factors that lead to a state of physiological hypercoagulability [2]. Thus, in comparison to non-pregnant women of the same age, pregnant women have an approximately 4–5 times higher risk of VTE [3]. The risk for VTE rises during pregnancy and peaks in the postpartum period [4].

This thrombotic risk which is anyway elevated by pregnancy increases further if additional intrinsic and extrinsic risk factors for VTE are present in the pregnant woman. Intrinsic risk means the increased proneness of pregnant women towards thrombotic events due to their individual characteristics, while extrinsic risk factors are factors which act on the pregnant woman externally and which situationally increase the risk of thrombosis [5]. Independent risk factors such as being 35 or older, null parity, multiple gestations, obesity, smoking and immobility, increase the risk by a factor of 1.5—2 [6, 7]. Certain other predisposing conditions have been associated with a higher risk of PA-VTE. These include inherited or acquired thrombophilia, a previous history of thrombosis, antiphospholipid syndrome, and other co-morbidities. When these are present, the need for prophylactic anticoagulation should be addressed [6].

The pro-coagulant state of pregnancy could also expose a woman to the possibility of gestational vascular complications (GVCs) (pre-eclampsia, placental abruption, fetal growth restriction (FGR), late and recurrent early miscarriage, intrauterine death and stillbirth), especially in the presence of acquired or inherited thrombophilia [8–10]. Antiphospholipid antibodies (APLA), including lupus anticoagulant (LAC), anticardiolipin antibodies (ACL) and b-2 glycoprotein antibodies (B2GP) are autoimmune antibodies directed against phospholipid-binding plasma proteins and they have been associated with both arterial and venous thrombosis as well as pregnancy morbidities [10].

Low-molecular-weight heparins (LMWHs) are effective thrombo-prophylactic agents; they do not cross the placenta, and they do not appear in breast milk [11–14]. However, the use of LMWH prophylaxis during pregnancy to prevent recurrent adverse pregnancy complications is supported by limited and conflicting evidence [15].

In an attempt to improve Assisted Reproduction Techniques (ART) outcomes many studies have investigated the effects of low-dose aspirin or low-molecular-weight heparin (LMWH), because of their antithrombotic and vasodilatory properties. The biological plausibility of antithrombotic prophylaxis may be represented by a beneficial effect in counteracting existing or developing at risk pro-thrombotic conditions [16]. However, the data are controversial.

In Greece LMWHs are used extensively during pregnancy and puerperium for VTE treatment and prophylaxis and for a variety of other indications as well. In this context, we conducted a cohort study [17] in an attempt to elucidate the clinical practice in our country, with the aim of gaining insights regarding the use of LMWHs during pregnancy and puerperium, describing the indications for use, the diagnostic work-up as well as the safety and efficacy of the treatment.

In our previous work we presented data regarding LMWH use in pregnancy for VTE management and the optimization of pregnancy and ART outcomes, with a sample of 818 women receiving LMWH during 2010–2015. There were 4 groups: those with a history of VTE [Group-A: 76], those with pregnancy complications [Group-B: 445], those undergoing IVF [Group-C: 132] and those with a prothrombotic tendency (thrombophilia, family history of VTE, other) [Group-D: 165].

For Group A, the administration of thromboprophylaxis has been well supported by studies and is recommended by existing guidelines. However, for Groups B, C & D clinical decisions about thromboprophylaxis management were based mainly on clinical experience. Specifically, for Group B, the use of LMWH prophylaxis during pregnancy to prevent recurrent GVCs is supported by limited and conflicting evidence and thus it is not recommended at present by guidelines with the exception of women with APLA. For Group C, for the women on IVF, the data are controversial and there is no clear recommendation. While for Group D, the inherited thrombophilia by itself does not necessitate thromboprophylaxis during pregnancy and puerperium.

When dealing with pregnant women, apart from clinical experience, further considerations come into play and all known intrinsic and extrinsic risk factors of the pregnant woman must be taken into account. For this reason, we constructed a digital VTE-risk assessment tool – PATrisks (www.PATrisks.com) based on related RCOG-guidelines [18]. The elevated baseline pregnancy-associated VTE risk necessitates VTE risk assessment in early pregnancy, at delivery, and if the risk factors change.

In order to further analyze our extended available data to gain more insights into the rationale behind LMWHs use in pregnant women with no clear recommendation for thromboprophylaxis, we proceeded in a post-hoc analysis of our previous work cohort and evaluated them for VTE risk retrospectively using PATrisks.

The aim of this study is.

a) To investigate if the administration of LMWH in pregnant women of Groups B, C & D (which in
this study have been renamed as Groups A, B & C respectively) was justified by the scoring system used for VTE prevention
b) To assess the women’s status and to provide details concerning thrombophilia

Methods
This study adds to the results of our previous study [17], a multicenter, retrospective study that addressed the issue of LMWH use in pregnant women in Greece, and which used as its subjects 818 pregnant women receiving LMWH for prophylaxis based on clinical experience. For the purpose of our post-hoc analysis, women with pregnancy complications [Group-A: 445], those undergoing IVF [Group-B: 132] and those with a prothrombotic tendency (thrombophilia, family history of VTE, other) [Group-C: 165] were assessed via the PATrisky scoring system in order to evaluate their thrombotic risk. Women with a personal history of VTE [categorized as Group-A: 76, in our previous study], were not analyzed since all these women were by definition in a high risk category (scoring 4 in PATrisky) and therefore the administration of thrombophylaxis was clearly recommended anyway.

The risk score was calculated retrospectively and women were assigned into one of the following risk categories: low (score ≤ 2), intermediate (score = 3) and high (score ≥ 4). Further analysis per risk factor type (pre-existing or obstetric) and combinations of them, was also performed; we evaluated the risk first early in pregnancy, and secondly in the peripartum period, as many risk factors are associated with delivery.

Furthermore, we conducted a detailed descriptive analysis of the incidence of thrombophilic defects. The thrombophilic defects were grouped into four categories: a) high risk hereditary thrombophilias including AT III deficiency (<70%), homozygous FV G1691A, homozygous FII G20210A, combined heterozygous FV G1691A & FII G20210A, Protein C (PC, <70%) & Protein S (PS, <60%) deficiency, b) low risk hereditary thrombophilias including heterozygous FV G1691A & heterozygous FII G20210A, c) acquired thrombophilia including APLA and d) other low-risk thrombophilias including MTHFR and PAI4G.

Statistical analysis
The statistical analysis was performed by the SAS for Windows 9.4 software platform [19] (SAS Institute Inc., NC, U.S.A.). The demographic and clinical data of the patients at the baseline were presented via descriptive statistics. Specifically, as the mean value and standard deviation (SD) and for reasons of completeness the median value and the values for 25% and 75% percentiles were also reported, for the qualitative data, frequencies and percentages were presented. Comparisons between two or more groups for the categorical parameters were performed using the chi-square test [20]. For the quantitative parameters (for example the women’s age) the Mann–Whitney U test was applied for comparison between two groups or the Kruskal–Wallis test when more than two groups were involved [19] respectively; as normality was not always certain. For paired analysis, i.e. to compare the PAT risk pre and post-partum, the Wilcoxon Signed Rank test was applied. The significance level (p-value) of the study was set to 0.05 and all tests were two-sided.

Results
Study population
In terms of the baseline and treatment characteristics between women with pregnancy complications [Group-A: 445] and those with a prothrombotic tendency (thrombophilia, family history of VTE, other) [Group-C: 165] there were no significant differences in general; those undergoing IVF [Group-B: 132] were of a higher age (37.2±5.1), one out of five had multiple pregnancy (30, 22.7%) and concomitantly received aspirin more frequently (30.3%). In terms of outcomes, again there were differences between the groups; specifically, in Group B the frequency of GVCs was almost twice as high in comparison with that of Group A and Group C, mainly driven by differences in IUGR and early pregnancy loss events. The characteristics of the study population are presented in Table 1.

Variation of the risk among the studied groups
The mean score antepartum was higher for women in Group B (3.3 in comparison with 1.9 and 2.0 in Group A and Group C respectively). Moreover, the risk score increased significantly postpartum for all Groups. The descriptive characteristics of the VTE risk score for each group, are presented in Table 2.

Afterwards, the differences in the risk scores between the three groups were compared by two methods: a) as an arithmetic score and b) as a qualitative measure (i.e. after being characterized as: low, intermediate and high).

A graphical representation of the results of the first approach (arithmetic score) is presented in Fig. 1. The statistical test indicated a significant difference in the scores between the three groups both before (p < 0.0001) and after birth (p < 0.0001). The results of the investigation by score characterization that we conducted, are presented in Table 3. The data for risk antepartum and risk postpartum are presented separately. It is interesting to note that group B had a higher percentage of women at high risk (25.76%
and 60.61% before and after delivery) compared to group A (18.88% and 28.31%) and group C (15.15% and 28.48%). A significant difference ($p < 0.0001$) was found in all comparisons between group B vs. group A or C.

Actually, group A and C have a lower distribution of the women in the high or intermediate risk group, while in group B 55.3% of the women were at intermediate or high risk before delivery and this percentage increased further after delivery (85.6%). The chi-square test also proved that there is a higher percentage of women at high or intermediate risk in group B compared to C before birth (55.3% vs. 26.1% respectively, $p < 0.0001$, OR: 3.5, 95% CI: 2.2 – 5.7) and similarly after birth (85.6% vs. 56.4%, OR: 4.6, 95%CI: 2.6 – 8.2, $p < 0.0001$).

When comparing group B with the combined figures for groups A and C, we found that before birth the odds for Intermediate or high risk in group B were 3.8 times higher (95% CI: 2.6 – 5.6, $p < 0.0001$) than the odds in groups A and C combined (see Table 4), while after birth the OR was almost twice as high (7.0, 95% CI: 4.2 – 11.7, $p < 0.0001$).

### Table 1
Characteristics of the study population organized according to the groups and according to demographic/medical record, anticoagulation treatment, and outcomes (gestation related and coagulation related)

|                      | Group A $N = 445$ | Group B $N = 132$ | Group C $N = 165$ | p       |
|----------------------|-------------------|-------------------|-------------------|---------|
| **Baseline**         |                   |                   |                   |         |
| Age (mean ± SD)      | 33.5 ± 4.6        | 37.2 ± 5.1        | 32.5 ± 4.4        | <.0001  |
| BMI (mean, SD)       | 24.4 ± 3.9        | 24.7 ± 3.8        | 24.4 ± 4.3        | 0.4281  |
| No. of foetuses at the observed gestation (N, %) |                   |                   |                   |         |
| ≥ 1                  |                   | 102, 77.3%        | 158, 95.8%        |         |
| > 2                  |                   | 30, 22.7%         | 7, 4.2%           |         |
| **High risk Thrombophilia (positive cases)** |                   |                   |                   | 0.9916  |
| ≥ 2                  |                   | 10.10%            | 9.90%             |         |
| Treatment            |                   |                   |                   |         |
| Mean Duration of LMWH (months) | 8.7 ± 1.3 | 8.7 ± 1.7 | 8.3 ± 1.6 | <.0001  |
| Fixed Prophylactic Dose | 58.90%    | 50%               | 52.10%            | 0.1100  |
| Weight Adjusted prophylactic dose | 32.40%    | 38.60%            | 37.00%            | 0.3902  |
| Therapeutic dose of LMWH | 8.80%     | 11.40%            | 10.90%            | 0.5663  |
| Concomitant Use of ASA | 18.20%    | 30.30%            | 12.10%            | 0.0003  |
| Outcomes             |                   |                   |                   |         |
| Caesarian            | 79.78%            | 91.28%            | 65.50%            | <.0001  |
| Live Birth           | 99.10%            | 97.00%            | 99.40%            | 0.1039  |
| Gestational Vascular Complications (Total) | 37 (8.3%) | 23 (17.4%) | 16 (9.7%) | 0.0097  |
| IUGR                 | 13 (2.9%)         | 8 (6.1%)          | 5 (3.0%)          | 0.2114  |
| Preterm Labor        | 19 (4.3%)         | 12 (9.1%)         | 10 (6.1%)         | 0.0978  |
| Fetal Death          | 1 (0.2%)          | 1 (0.8%)          | 0.5981            |
| Early pregnancy loss/abortion | 3 (0.7%) | 2 (1.5%) | 0.5427            |
| Pre-eclampsia/eclampsia | 1 (0.2%) | 1(0.6%)         | 0.6301            |
| VTE [VTE postpartum]$^a$ | 3 (0.7%) [3 (0.7%)] (5 women) | 0 [1 (0.8%)] [1 woman] | 0 [1 (0.6%)] [5 (3.0%)] (6 women) | 0.0632  |
| Bleeding             | 6 (1.3%)          | 5 (3.8%)          | 1 (0.6%)          | 0.0728  |

$^a$ Indicates the VTE events during gestation, the figures within square brackets depict the VTE events during the postpartum period, while the figures in parentheses indicate the number of women involved.

### Table 2
Descriptive characteristics of score points for each group. SD: Standard Deviation, Min: minimum, Max: Maximum, Q1: Quartile 1, Q3: Quartile 3

| Group      | N  | Mean | SD  | Median | Q1  | Q3  | Mean | SD  | Median | Q1  | Q3  | p     |
|------------|----|------|-----|--------|-----|-----|------|-----|--------|-----|-----|-------|
| Group A    | 445| 1.9  | 2.2 | 1      | 1   | 2   | 3.1  | 2.3 | 2      | 2   | 4   | <0.0001|
| Group B    | 132| 3.3  | 2.1 | 3      | 2   | 4   | 4.6  | 2.3 | 4      | 3   | 6   | <0.0001|
| Group C    | 165| 2.0  | 1.7 | 2      | 1   | 3   | 3.2  | 1.9 | 3      | 2   | 4   | <0.0001|
Coexistence of risk factors in the groups studied

In actual fact, the separation of women into the three groups studied is not the only one possible since women may have more than one reason for being included in the study, and thus they could have potentially been included in more than one group. Within the source study [17], women were assigned to a group on the basis of one basic reason only. However multiple reasons could exist and the distribution of the women according to these reasons is depicted in Table 5. Actually 81.4% of the women in the study had a single reason while the remaining 18.6% had multiple reasons and thus these women had an increased
Observed risk components
With regard to the two major risk components that go into the calculation of the PATrisks score, that is a) pre-existing risk factors and b) obstetric risk factors, the distribution of the population studied according to the individual components is depicted in Table 6. A small percentage 11% had no risk factor, while 38% and 8% had only obstetric and pre-existing risk factors respectively; moreover, almost 43% of the women in the study, had simultaneously more than a single factor, that is, they had both pre-existing and obstetrics risk factors.

Risk score and thrombotic events
In total 12 (1.6%) out of 742 women included in our analysis experienced thrombotic events, whether pre- or post-partum, during the study period (see Table 1 [one woman had two thrombotic events]). The median value of the risk score for the women experiencing thrombosis was 2.5 (Q1-Q3: 0.5–2.5) before birth and this score rose to a median value of 3.5 (Q1-Q3: 2–3.5) after delivery. There was no significant difference in the score between the women who did and did not experience such events whether before (p = 0.4319) or after delivery (p = 0.4004) (see Fig. 3 for the relevant diagram), probably due to the anticoagulation prophylaxis given to all participating

### Table 5 Reasons harbored by individual women

| Reason                                      | N   | %    |
|---------------------------------------------|-----|------|
| IVF only                                    | 92  | 12.4%|
| History of GVCs a only                      | 350 | 47.2%|
| Other only b                               | 162 | 21.8%|
| IVF & History of GVCs                      | 33  | 4.4% |
| IVF & other                                | 19  | 2.6% |
| History of GVCs & other                    | 83  | 11.2%|
| IVF & History of GVCs & other              | 3   | 0.4% |

*a* Early pregnancy loss, fetal death, eclampsia/preeclampsia and IUGR

*b* Including family history of thrombophilia and/or thrombophilia

### Table 6 Risk component harbored by the participating women

| Risk component                      | N   | %    |
|-------------------------------------|-----|------|
| none                                | 83  | 11.19% |
| Pre-existing                        | 61  | 8.22% |
| Obstetrics                          | 280 | 37.74% |
| Pre-existing & obstetrics           | 318 | 42.86% |

**Fig. 2** Venn diagram depicting the distribution of women into the various categories according to their reason for inclusion
women. It is interesting to note that some women with high risk (score > 10) did not experience thrombotic events. Among women who did experience thrombosis, five had a low score, one had an intermediate score (i.e. 3) and the remaining 6 had a score higher than 4 (high risk).

The analysis of the six women with a low or intermediate score showed that two were in group A and four in group B while none were in group C. Out of these six women, one had a family history for thrombosis, one had a multiple pregnancy, one received blood transfusion and four had low risk thrombophilia; in addition, the one with the family history of VTE had a BMI of 42.1. Five out of the six thrombotic events were postpartum when no prophylaxis was applied, precisely because they had low risk score for VTE.

Analysis of thrombophilia factors observed in the various groups

Of special interest is the distribution of high-risk thrombophilia observed in the study.

The figures indicating the presence of thrombophilia risk factors per Group and in Total are given in Table 7. Women with APLA who were in group B had a higher PATrisks score.

Out of the total study population of 742 women, 149 of them (20.1%) had high-risk thrombophilia (note that many women had multiple thrombophilias); specifically, there were 96 of them in group A, 26 in group B and 27 in group C, representing 21.6%, 19.7% and 16.4% out of each individual group population respectively. No statistically significant difference was found in the percentages of population with high-risk thrombophilia in the groups studied (p > 0.05 in all comparisons). Low-risk thrombophilia was observed in 83.7% of the total population, that is 82.3% in group A, 81.1% in group B and 89.7% in Group C; no significant difference was found between groups A and B (p = 0.7554); however, there was noticeable differences between groups A and C (OR: 1.9, 95% CI: 1.1—3.3, p = 0.0248) as well as between groups B and C (OR: 2.0, 95% CI: 1.0—4.0, p = 0.0338). However, the low risk factors with well-established association with VTE such as the heterozygous mutations for FV Leiden and FII 20,210 were found in 39.1% and 21.1% of the total population respectively (difference 18%, 95%CI: 13.3–22.6%, p < 0.0001). Finally, none of the thrombophilia risk factors presented in Table 7 was observed in 102 of the women (13.7% of the total population); these women were distributed as follows: 66 in group A (14.8% of the group population), 23 in group B (17.4%) and 13 in group C (7.9%).

![Fig. 3 Box and whisker plots of the risk score for the women who did and did not experience thrombotic event during the study. Box limits show the 1st and 3rd quartiles, whisker limits show the minimum and maximum values (excluding outliers), while the lines and diamonds within the boxes correspond to the median values and the mean values respectively](image)
Discussion

Summary of the key findings

In this post-hoc analysis, we retrospectively evaluated thrombotic risk in women who received LMWH based on clinical experience hoping to optimize their pregnancy outcome, so that we could investigate whether that practice was justified according to the PATrisks scoring system. The arithmetic mean score antepartum was higher for women in Group B (3.3) in comparison with that in Group A and Group C (1.9 and 2.0 respectively). This risk score increased significantly postpartum for all Groups. On the basis of the score characterization as high, intermediate and low, group B had a statistically significant higher percentage of women at high risk (25.76% and 60.61%, before and after delivery) compared to group A (18.88% and 28.31%) and group C (15.15% and 28.48%) in all comparisons. In relation to the major risk components that go into the calculation of the PATrisks score, a small percentage of women (11%) had no risk factor, while 38% and 8% had only obstetric and pre-existing risk factors respectively; moreover, almost 43% of women had more than a single risk factor type simultaneously.

In total, 12 (1.6%) out of the 742 women included in our analysis experienced thrombotic events during the study. The median value of the risk score for the women experiencing thrombosis was 2.5 (Q1-Q3: 0.5–2.5) before birth and this score increased to a median value of 3.5 (Q1-Q3: 2–3.5) after delivery. No significant difference was found in the score between the women who did and did not experience such events either before ($p = 0.4319$) or after delivery ($p = 0.4004$).

Out of the total study population, 149 (20.1%) women had high risk thrombophilia; specifically 21.6% in group A, 19.7% in group B and 16.4% in group C. Absence of thrombophilia risk factors was observed in 102 women (13.7% of the total population), specifically in 14.8%, 17.4% and 7.9% of the women in groups A, B and C respectively.

Although an established VTE in pregnancy may be successfully treated with therapeutic doses of heparin, prevention is preferable to cure because of the high mortality and long-term morbidity associated with established disease [21, 22]. LMWHs can be used safely in pregnancy and in breastfeeding with no adverse effects on the fetus or the neonate. Medical prophylaxis against thrombosis starts during pregnancy and is generally continued for about six weeks following delivery due to the risk of thrombosis which peaks during the postpartum period. Because of their efficacy and good safety profile, the use of low molecular weight heparins for thromboprophylaxis in pregnancy has increased greatly in recent years. Their use has also increased in women at high risk of GVCs and for the optimization of ART outcomes in anticipation of the scientific evidence in favor of their use becoming available. Clinicians have proposed these treatments on the grounds of biological plausibility and on the basis of extrapolation from antiphospholipid syndrome [23]. There is also increasing evidence for the use of heparin in women with pregnancy complications mediated

### Table 7

| Factor | Number of cases, median [q1—q3] | Total, $p$-value |
|--------|---------------------------------|-----------------|
|        | Group A                         | Group B         | Group C         |
| High risk inherited Reduced levels of ΑΤ ($<$ 70%) | 6, 8.5 [6—8.5] | 2, 7.5 [7—7.5] | 3, 7 [4—7] | 11, 0.7659 |
|        | Reduced levels of PC ($<$ 70%)  | 7, 7 [6 - 7]    | 1, 11 [11 - 11] | 1, 11 [11 - 11] | 9, 0.116 |
|        | Reduced levels of PS F ($<$ 60%) | 11, 7 [6 - 7]  | 4, 7.5 [6.5—7.5] | 3, 7 [6—7] | 18, 0.6525 |
|        | Reduced levels of PS C ($<$ 60%) | 9, 6 [6 - 6]  | 2, 10 [8 - 10] | 3, 4 [4 - 4] | 14, 0.1403 |
|        | FV Leiden homozygous aa         | 7, 6 [4 - 6]  | 2, 7 [5 - 7] | 7, 7 [6 - 7] | 16, 0.6533 |
|        | FII20210 homozygous aa          | 2, 7 [6 - 7]  | 1, 8 [8 - 8] | 1, 5 [5 - 5] | 4, 0.3247 |
|        | FV Leiden and FII20210 combined heterozygous ga | 11, 7 [7 - 7] | 1, 12 [12 - 12] | 0, [-] | 12, 0.0973 |
| High risk acquired APLA syndrome | 56, 6 [6 - 6] | 16, 8 [8 - 8] | 11, 6 [4 - 6] | 83, <0.0001 |
| Low risk inherited FV Leiden heterozygous ga | 136, 4 [4 - 4] | 32, 6 [5.5—6] | 59, 4 [2 - 4] | 227, <0.0001 |
|        | FII20210 heterozygous ga        | 67, 4 [4 - 4] | 21, 6 [5 - 6] | 30, 4 [2 - 4] | 118, 0.0038 |
| Other low risk MTHFR | 297, 4 [3 - 4] | 95, 6 [5 - 6] | 114, 4 [2 - 4] | 506, <0.0001 |
|        | PA14G                           | 148, 4 [3 - 4] | 44, 6 [5 - 6] | 80, 4 [2 - 4] | 272, <0.0001 |
| Factor XII above normal range (50–150) | 6, 3 [1 - 3] | 4, 11 [10 - 11] | 3, 3 [3 - 3] | 13, 0.0167 |
| Factor VIII above normal range (50–150) | 8, 7 [3.5—7] | 6, 11 [10 - 11] | 3, 8 [4 - 8] | 17, 0.0454 |
| Other low-ris  | 51, 3 [1 - 3] | 24, 5.5 [5–5.5] | 33, 3 [1 - 3] | 108, <0.0001 |
by the placenta (as can be seen from successful previous pregnancy outcomes), while this is not the case for women with thrombophilic defect alone [24].

In our cohort, administration of LMWH for VTE prevention was found to be both efficacious and safe; only 1.6% of the total women population included in our analysis experienced thrombotic events (whether pre-or post-partum) during the study, and the prevalence of bleeding events was also low.

From our analysis we found that despite the fact that the administration of LMWHs in all groups was based on clinical experience, in one out of four women for Groups A & C and in more than half of women in Group B this was justified antepartum by the scoring tool since they were found to have intermediate or high risk for VTE. Additionally, the administration of LMWHs postpartum was justified to a higher extend; specifically, almost half of the women in Groups A & C and more than eight out of ten in Group B were found to have intermediate or high risk, after birth. It is interesting to note that, regardless of which group they had been allocated to, the number of women with intermediate or high score was almost twice as high postpartum (393) as antepartum (223).

With regard to the major risk components that go into the calculation of the PATrisks score only one out of ten women had no risk factors at all, while 38% and 8% of them had only obstetric or pre-existing risk factors respectively; moreover, almost 43% of the women, had both pre-existing and obstetrics risk factors simultaneously. Those findings also provide, at least partially, justification for the administration of LMWH in the population under study.

Robertson et al. [25] conducted a large systematic review to assess the overall relationship between all major thrombophilia and adverse pregnancy outcomes, which comprised 79 studies, primarily consisting of case–control studies. All inherited thrombophilia defects were associated with venous thromboembolic disease (VTE), homozygous/ heterozygous FV G1691A and FII G20210A were associated with pregnancy loss <24 weeks [Odds ratio (OR) 2.71, 1.68, 2.49 respectively], heterozygous FV G1691A, FII G20210A, and PS with pregnancy loss >24 weeks (OR 2.06, 2.66, 20.09), heterozygous FV G1691A and FII G20210A with PE (OR 2.19, 2.54), and heterozygous FV G1691A and FII G20210A with PA-VTE (OR: 4.70, 7.71).

That being so, in the PATrisks tool all the “high risk thrombophilias” (Table 7) are rated with 3 points, and from the “low risk thrombophilias” only the heterozygous mutations for FV Leiden and FII 20,210 are rated with 1 point. The “other risk thrombophilias” are not scored in the PATrisks tool because their association with the occurrence of VTE is not well established. Out of all the women in the study, one out of five had high risk thrombophilia and one out of ten had APLA; both conditions during pregnancy also provide a rationale for the use of thromboprophylaxis. Additionally, the low risk factors such as the heterozygous mutations for FV Leiden and FII 20,210 which were found in 39.1% and 21.1% of the total population respectively, again provides some rationale for primary prophylaxis from thrombotic events in the context of pregnancy and puerperium only if there are other preexisting or/and obstetrics risk factors.

In terms of pregnancy outcomes and despite the quite high prevalence of various thrombophilic disorders with known association with pregnancy complications, the frequency of GVCs in the pregnancies examined was low overall; the most frequently observed GVCs were pre-term labor and IUGR.

In our days, assisted reproductive technologies (ART) are widely used in couples with fertility problems and low-molecular-weight heparin (LMWH) is routinely administered in various cases to improve ART outcomes. The live birth rate in Group B of our cohort was 97% which is quite high for women undergoing assisted reproduction techniques, indicating a possible favorable effect of LMWH administration in successful ART outcomes. Live birth rates were also high (higher than 99%) in both Groups A & C.

This post-hoc analysis also shares the limitations, as well as the advantages, of most observational studies. By its design, the study involves a broad range of everyday/routine clinical approaches, and there is limited specific focus for the inclusion in Groups of the participating women. Thus, biases of an unknown nature may have colored the results. This study does not feature the typical separation of patients into case and control groups—instead, the analysis involved all patients in an intention-to-treat manner. This list of limitations is by no means exhaustive. However, in the authors’ opinion, this study has the potential to capture the “in vivo” conditions of a common clinical obstetrics setting. We recognize that a control group of patients would strengthen the analysis. As we mentioned before, the study is retrospective, and it is a post hoc analysis of our previous work [17]. Pregnant women had received LMWH hoping to achieve a good pregnancy outcome. Their data were analyzed retrospectively to determine whether LMWH could provide to some of them an additional benefit as thromboprophylaxis, according to the PATRisks score which is based on RCOG guidelines. These guidelines have emerged from older, large studies which recognize the increased risk of VTE in pregnancy and postpartum [1–3, 18]. In the future, we would like to study the prospective evaluation of the PATRisks score in pregnancy.
Conclusions
LMWHs are widely prescribed during pregnancy for a variety of indications with no proven scientific basis for all of them, due to the lack of randomized trials. However, a considerable percentage of women with pregnancy complications, those undergoing IVF, and those carrying prothrombotic tendencies who are treated with LMWH were already at VTE-risk according to PATrisks and might have derived an additional benefit from LMWH in the form of VTE prevention. The rational use of these drugs should be optimized by establishing and implementing routine risk assessment for all pregnant women and by providing the necessary education to healthcare professionals.

Abbreviations
ACL: Anticardiolipin antibodies; APLA: Antiphospholid antibodies; ART: Assisted Reproduction Techniques; ASA: Acetylsalicylic acid; AT: Antithrombin; B2GP: B-2 glycoprotein antibodies; BMI: Body mass index; DVT: Deep vein thrombosis; CS: Caesarian section; FGR: Fetal growth restriction; GVCs: Gestational vascular complications; IUGR: Intrauterine growth retardation; IVF: In Vitro Fertilization; LAC: Lupus anticoagulant; LMWHs: Low molecular weight heparins; OR: Odds Ratio; PA-VTE: Pregnancy-associated Venous thromboembolism; PC: Protein C; PE: Pulmonary embolism; PS: Protein S; Q1: Quartile 1; Q2: Quartile 2; RCOG: Royal College of Obstetricians and Gynecologists; SD: Standard Deviation; VTE: Venous thromboembolism.

Acknowledgements
N/A

Authors’ contributions
EG, ER AA, AC, PK, GA, AF, designed the study and enrolled patients and patient data. EG, AP, EP wrote the first draft of the manuscript and the final version. AP performed the statistical analysis and constructed the tables and the graphs of the manuscript. All authors read and approved the final manuscript.

Funding
This study received no funding.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The study was approved by the ethic committees of the participating institutions. Informed oral consent was obtained from each pregnant woman.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests.

Author details
Grouzi et al. Thrombosis Journal (2022) 20:60
Page 10 of 11

References
1. Blondon M, Casini A, Hoppe KK, Boehlen F, Righini M, Smith NL. Risks of venous thromboembolism after cesarean sections: a meta-analysis. Chest. 2016;150(3):572–96.
2. Gray G, Nelson-Piercy C. Thromboembolic disorders in obstetrics. Best Pract Res Clin Obstet Gynaecol. 2012;26(1):53–64.
3. Heit JA, Kobbervig CE, James AH, Pettersson TM, Bailey KR, Melton LJ 3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143(10):697–706.
4. Abdul Sultan A, Tata LJ, Grainge MJ, West J. The incidence of first venous thromboembolism in and around pregnancy using linked primary and secondary care data: a population based cohort study from England and comparative meta-analysis. PLoS ONE. 2013;8(7):e70310.
5. Sucker C. Prophylaxis and therapy of Venous Thrombotic Events (VTE) in pregnancy and the postpartum period. Geburtshilfe Frauenheilkd. 2020;80(1):48–59.
6. James AH, Jamison MG, Brancacio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194(5):1311–5.
7. Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium—a register-based case-control study. Am J Obstet Gynecol. 2008;198(2):233.e231-237.
8. Aracic N, Roje D, Jakus IA, Bakotin M, Stefanovic V. The impact of inherited thrombophilia types and low molecular weight heparin treatment on pregnancy complications in women with previous adverse outcome. Yonsei Med J. 2016;57(5):1230–5.
9. Middeldorp S. Pregnancy failure and heritable thrombophilia. Semin Hematol. 2007;44(2):93–7.
10. Rai R, Regan L. Recurrent miscarriage. Lancet. 2006;368(9535):601–11.
11. Nelson-Piercy C, Powrie F, Bogg JY, Rodger M, Talbot DJ, Stinson J, Greer IA. Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile. Eur J Obstet Gynecol Reprod Biol. 2011;159(2):293–9.
12. Ellison J, Walker D, Greer IA. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. BJOG. 2000;107(9):1116–21.
13. Matzsch T, Bergqvist D, Bergqvist A, Hodson S, Dawes J, Hedner U, Ostergaard P. No transplacental passage of standard heparin or an enzymatically depolymerized low molecular weight heparin. Blood Coagul Fibrinolysis. 1991;2(2):273–8.
14. Richter C, Sitzmann J, Lang P, Weitzel H, Huch A, Huch R. Excretion of low molecular weight heparin in human milk. Br J Clin Pharmacol. 2001;52(6):708–10.
15. Skeith L, Rodger M. Anticoagulants to prevent recurrent placenta-mediated pregnancy complications: Is it time to put the needles away? Thromb Res. 2017;151(1):538–42.
16. Quaranta M, Erez O, Mastrolia SA, Kofman A, Lerom E, Eshkoli T, Mazor M, Holberg G. The physiologic and therapeutic role of heparin in implantation and placentation. PeerJ. 2015;3:e691.
17. Papadakis E, Poulakis A, Akypri A, Chrestoforidou A, Kotsi P, Alphanagnostou G, Golia A, Grouzi E. Low molecular weight heparins use in pregnancy: a practice survey from Greece and a review of the literature. Thromb J. 2019;17:23.
18. Royal College of Obstetricians and Gynaecologists. Thrombosis and Embolism during Pregnancy and the Puerperium, Reducing the Risk (Green-top Guideline No. 37a). 2015 [https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg37a/]. Accessed: 15 Nov 2021.
19. DiMaggio C. SAS for epidemiologists: applications and methods. New York: Springer; 2013.
20. Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS system. 2nd ed. Cary, NC: SAS Institute; 2000.
21. Lindhagen A, Bergqvist A, Bergqvist D, Hallbook T. Late venous function in the leg after deep venous thrombosis occurring in relation to pregnancy. Br J Obstet Gynaecol. 1986;93(4):348–52.
22. Bergqvist A, Bergqvist D, Lindhagen A, Matzsch T. Late symptoms after pregnancy-related deep vein thrombosis. Br J Obstet Gynaecol. 1990;97(4):338–41.
23. Greer IA, Aharon A, Brenner B, Gris JC. Coagulation and placenta-mediated complications. Rambam Maimonides Med J. 2014;5(4):e0034.
24. Rodger MA, Hague WM, Kingdom J, Kahn SR, Karovitch A, Sermer M, Clement AM, Coat S, Chan WS, Said J, et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet. 2014;384(9955):1673–83.
25. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, Walker ID, Greaves M, Brenkel I, Regan L, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006;132(2):171–96.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.